CGTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
7.7M
-12.2%
8.8M
-35.5%
13.7M
+114.4%
6.4M
-54.4%
14.0M
R&D
5.1M
-16.7%
6.1M
-45.1%
11.1M
+195.4%
3.8M
-67.1%
11.5M
SG&A
2.6M
-2.1%
2.7M
+6.9%
2.5M
-3.0%
2.6M
+4.2%
2.5M
Operating Income
-7738000
+12.2%
-8817000
+35.5%
-13671000
-114.4%
-6375000
+54.4%
-13978000
EBITDA
-7728000
+12.2%
-8806000
+35.5%
-13657000
-114.7%
-6360000
+54.4%
-13962000
Net Income
-3932000
+14.0%
-4570000
-36.7%
-3343000
+32.2%
-4930000
+26.8%
-6734000
EPS (Basic)
$-0.04
+20.0%
$-0.05
-25.0%
$-0.04
+33.3%
$-0.06
+45.5%
$-0.11
EPS (Diluted)
$-0.04
+20.0%
$-0.05
-25.0%
$-0.04
+33.3%
$-0.06
+45.5%
$-0.11
Shares (Diluted)
90.6M
+1.6%
89.2M
+1.8%
87.6M
+12.4%
78.0M
+22.4%
63.7M
Cognition Therapeutics (CGTX) โ€” Financials